Back

Liver Endothelium Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer Cells

Rathore, M.; Wright, M.; Bhattacharya, R.; Fan, F.; Vaziri-Gohar, A.; Winter, J.; Wang, Z.; Markowitz, S.; Willis, J.; Ellis, L.; Wang, R.

2021-06-23 cancer biology
10.1101/2021.04.27.441690 bioRxiv
Show abstract

We previously showed that liver endothelial cells (ECs) secreted soluble factors in a paracrine fashion and activated human epidermal growth factor receptor 3 (HER3, also known as ERBB3) for promoting colorectal cancer (CRC) growth and chemoresistance. However, RAS proteins play a critical role in receptor tyrosine kinase signaling pathways, and KRAS mutations mediate CRC resistance to therapies targeting EGFR, another HER protein. Therefore, the role of KRAS mutation status in EC-induced HER3 activation and CRC survival was investigated as it has therapeutic implications. We used CRC cell lines and patient-derived xenografts harboring KRAS wild-type or mutant genes and demonstrated that liver EC-secreted factors promoted HER3-mediated CRC cell growth independent of KRAS mutation status. Also, blocking HER3 in CRC cells by siRNAs or a HER3 antibody seribantumab blocked EC-induced CRC survival. Our findings highlight the potential of utilizing HER3 targeted therapies for treating patients with mCRC independent of RAS mutational status.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Scientific Reports
○ 3612 papers in training set
Top 11%
6.5%
Similar papers in this journal
2
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.2%
4.7%
Similar papers in this journal
3
Cancers
○ 213 papers in training set
Top 1%
4.2%
Similar papers in this journal
4
BMC Cancer
○ 67 papers in training set
Top 0.4%
4.2%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 29%
4.2%
6
Cancer Medicine
○ 26 papers in training set
Top 0.2%
4.2%
Similar papers in this journal
7
The American Journal of Pathology
○ 32 papers in training set
Top 0.1%
3.9%
8
Gastroenterology
○ 42 papers in training set
Top 0.2%
3.9%
9
Translational Oncology
○ 21 papers in training set
Top 0.1%
3.9%
10
Hepatology
○ 22 papers in training set
Top 0.1%
3.9%
11
Frontiers in Oncology
○ 103 papers in training set
Top 0.9%
3.9%
12
International Journal of Cancer
○ 49 papers in training set
Top 0.3%
3.3%
50% of probability mass above
13
British Journal of Cancer
○ 49 papers in training set
Top 0.4%
3.1%
14
Cancer Letters
○ 35 papers in training set
Top 0.3%
2.7%
15
Cellular and Molecular Gastroenterology and Hepatology
○ 46 papers in training set
Top 0.5%
2.1%
16
Gastro Hep Advances
○ 11 papers in training set
Top 0.2%
1.7%
17
Cancer Research
● 130 papers in training set
Top 2%
1.6%
18
Neoplasia
○ 23 papers in training set
Top 0.3%
1.6%
19
PLOS ONE
● 5266 papers in training set
Top 49%
1.5%
20
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.7%
1.5%
21
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1%
1.5%
22
Cell Death & Disease
147 papers in training set
Top 2%
1.3%
23
eBioMedicine
○ 183 papers in training set
Top 5%
1.1%
24
Gut
● 40 papers in training set
Top 0.7%
1.1%
25
JCI Insight
● 277 papers in training set
Top 6%
1.1%
26
Cells
○ 249 papers in training set
Top 6%
1.0%
27
Cancer Research Communications
● 51 papers in training set
Top 2%
1.0%
28
Molecular Oncology
○ 55 papers in training set
Top 1%
1.0%
29
Nature Communications
○ 5641 papers in training set
Top 54%
1.0%
30
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.